

REMARKS

Claims 1-20 and 34-47, of which claims 7-8, 10, 12, and 38-40 are currently amended, appear in this application for the Examiner's consideration. The amendments to the claims 7-8, 10, 12, and 38-40 are made to add SEQ ID NOs to the claims where necessary. These changes are supported by the original claims and the specification. As no new matter is added, Applicant respectfully requests that the amendments be entered at this time.

The Examiner states that the peptide sequences in the claims are not present in the paper copy of the Sequence Listing and requests a new computer readable format (CRF) copy and a paper copy of the Sequence Listing that includes the sequences recited in the present claims.

In response, Applicant would like to draw the Examiner's attention to the paper copy of the Sequence Listing submitted on July 31, 2001. This Sequence Listing includes all the sequences appearing in the present claims. In particular:

Gly-X-Ser-Pro-Gln (SEQ ID NO: 6) recited in claims 7 and 38 appears on page 4 of the Sequence Listing;

Gln-Ser-Gly-Gln-Ser-Pro-Gln-Ser-Ile (SEQ ID NO: 9) recited in claims 8 and 39 appears on page 5 of the Sequence Listing;

Asn-Gly-Lys-Ser-Pro-Gln-Ala-Ala-Trp (SEQ ID NO: 8) recited in claims 8 and 39 appears on page 5 of the Sequence Listing;

Phe-Pro-Thr-Gly-Asp-Leu-Ala-Glu-Lys (SEQ ID NO: 7) recited in claims 10 and 40 appears on pages 4-5 of the Sequence Listing;

His-Ala-Gln-Arg-Arg-Pro-Trp-Ile-Arg (SEQ ID NO: 15) recited in claim 12 appears on page 6 of the Sequence Listing; and

Glu-Asp-Pro-His-Pro-Gln-Arg-Gly-Tyr (SEQ ID NO: 16) recited in claim 12 appears on page 7 of the Sequence Listing.

A CRF copy, as well as a statement that the content of the sequence listing information recorded in the CRF is identical to that of the paper copy and includes no new matter, were also submitted on July 31, 2001 (see Transmittal of Substitute Sequence Listing; Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures - copy enclosed). Accordingly, Applicant believes that the application satisfies the requirements for the nucleotide and/or amino acid sequence disclosure under 37 C.F.R 1.821-1.825.

Furthermore, in the interest of expediting the prosecution of this application, claims 7-8, 10, 12, and 38-40 have now been amended to include the sequence identifier (SEQ ID NO) set forth in the Sequence Listing.

The entire application, therefore, is believed to be in proper form as to these sequence listings. In addition, as the applicants are not aware of any material prior art, it is further believed that the entire application is in condition for allowance, early notification of which would be appreciated. Should the Examiner not agree, a personal or telephonic interview is respectfully requested to discuss any remaining issues in order to expedite the eventual allowance of the claims.

Date

2/18/04

Respectfully submitted,

Allan A. Fanucci 30,256

Allan A. Fanucci

(Reg. No.)

WINSTON & STRAWN LLP
CUSTOMER NO. 28765
(212) 294-3311